Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

Next Previous
Trial Profile

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Gilteritinib (Primary) ; Idarubicin (Primary) ; Midostaurin (Primary) ; Pegfilgrastim (Primary) ; Venetoclax (Primary) ; Granulocyte colony-stimulating factors
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

Most Recent Events

  • 11 May 2025 Planned End Date changed from 31 May 2026 to 31 May 2030.
  • 11 May 2025 Planned primary completion date changed from 31 May 2025 to 31 May 2030.
  • 10 Dec 2024 Results (n=88) of subgroup analysis assessing Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine were presented at the 66th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top